Olivier Molinier

Olivier Molinier

UNVERIFIED PROFILE

Are you Olivier Molinier?   Register this Author

Register author
Olivier Molinier

Olivier Molinier

Publications by authors named "Olivier Molinier"

Are you Olivier Molinier?   Register this Author

34Publications

1823Reads

11Profile Views

Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial.

Clin Cancer Res 2019 Oct 7;25(19):5759-5765. Epub 2019 Jun 7.

Department of Thoracic Oncology, Centre d'investigation clinique Institut national de la santé et de la recherche médicale 1425, Hospital Bichat-Claude Bernard, Assistance Publique-Hôpitaux de Paris, Paris-Diderot University (Paris 7), Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-2860DOI Listing
October 2019

Evidence of slight improvement in five-year survival in non-small-cell lung cancer over the last 10 years: Results of the French KBP-CPHG real-world studies.

Bull Cancer 2019 Apr 23;106(4):283-292. Epub 2019 Feb 23.

Hôpital de Meaux, respiratory medicine department, 6-8, rue Saint-Fiacre, BP 218, 77104 Meaux cedex, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2019.01.010DOI Listing
April 2019

ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study.

J Thorac Oncol 2016 Oct 25;11(10):1682-9. Epub 2016 Jul 25.

Cell Biology and Biotherapy Unit, National Cancer Institute "Pascale Foundation," Institute of Hospitalization and Scientific Care (IRCCS), Naples, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.05.036DOI Listing
October 2016

PARAMOUNT: Descriptive subgroup analyses of final overall survival for the phase III study of maintenance pemetrexed versus placebo following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.

J Thorac Oncol 2014 Feb;9(2):205-13

*Department of Thoracic Oncology, Lungen Clinic Großhansdorf, Großhansdorf, Germany; †Instituto de Biomedicina de Sevilla, University Hospital Virgen del Rocío, CSIC and Seville University, Seville, Spain; ‡San Camillo-Forlanini Hospital, Rome, Italy; §Le Mans Regional Hospital, Le Mans, France; ‖Jawaharlal Nehru Cancer Hospital and Research Center, Bhopal, India; ¶University Medical Center Hamburg-Eppendorf, Hamburg, Germany; #Eli Lilly and Company, Indianapolis, Indiana; **Eli Lilly and Company, Houten, The Netherlands; and ††Division of Medical Oncology, San Giuseppe Moscati Hospital, Avellino, Italy.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864153019
Publisher Site
http://dx.doi.org/10.1097/JTO.0000000000000076DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4132027PMC
February 2014

Major changes in lung cancer over the last ten years in France: the KBP-CPHG studies.

Lung Cancer 2013 Jul 29;81(1):32-8. Epub 2013 Mar 29.

Respiratory Medicine Department, General Hospital, 6-8 Rue Saint Fiacre, BP 218, 77104 Meaux CEDEX, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2013.03.001DOI Listing
July 2013

Epirubicin and ifosfamide in relapsed or refractory small cell lung cancer patients.

Lung Cancer 2012 Feb 9;75(2):213-6. Epub 2011 Aug 9.

Montpellier Academic Hospital, Service d'Oncologie Thoracique, Montpellier, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2011.07.012DOI Listing
February 2012

[Small cell lung carcinoma].

Rev Prat 2003 Apr;53(7):735-42

Unité d'oncologie thoracique Hôpital Arnaud-de-Villeneuve Centre hospitalier universitaire et Languedoc Mutualité nouvelles technologies 34295 Montpellier.

View Article

Download full-text PDF

Source
April 2003